•	Application No.	Applicant(s)
Notice of Allowability	10/625,604	KAMITAMARI ET AL.
	Examiner	Art Unit
	Brian J. Davis	1621
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to applicant's amendment and TD (7/5/05).		
2. The allowed claim(s) is/are <u>1-9</u> .		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 09/766,575. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/C Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. Interview Summary Paper No./Mail Da 08), 7. Examiner's Amend	ite l
·		

Application/Control Number: 10/625,604

Art Unit: 1621

DETAILED ACTION

Claim Objections Withdrawn

The objection to claims 1 and 3, outlined in the previous Office Action, has been overcome by applicant's amendment. The amendment corrects the claim text as appropriate.

103 Rejections Withdrawn

The various detailed rejections of claims 1-9 and 12 under 35 USC 103(a), outlined in the previous Office Action, have been overcome by applicant's amendment and declaration. The amendment cancels claim 12.

With respect to the remaining claims, and as had been previously discussed with applicant (Interview Summary 6/24/05), applicant's arguments and declaration have been carefully considered and are persuasive. The examiner is in agreement with applicant that the instant substituents and their specific positions on the ring of the salicylidene moiety and the effect this has on the optical purity of the product is neither taught nor suggested by the cited prior art. Applicant's superior results, as shown by the declaration, are an unexpected improvement.

Double Patenting Rejections Withdrawn

The rejection of claims 5 and 12 under the judicially created doctrine of obviousness-type double patenting, outlined in the previous Office Action, has been

overcome by applicant's submission of a terminal disclaimer and the cancellation of claim 12.

Allowable Subject Matter

Claims 1-9 are allowed. The following is an examiner's statement of reasons for allowance:

The closest prior art remains the prior art of record. As discussed above and in applicant's response and declaration, the cited prior art neither teaches nor suggests the instant compounds and methods. Nor would it have been obvious to one of ordinary skill in the art at the time of invention to modify the teachings of the prior art in order to arrive at those of the instant invention. There is no motivation to do so.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J. Davis whose telephone number is 571-272-0638. The examiner can normally be reached on 8:30-5:00.

Application/Control Number: 10/625,604 Page 4

Art Unit: 1621

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brian J. Davis

Brian J. Davis July 18, 2005